Table 3.
Outcome at 12 months follow up
| Parameters | Comprehensive care | Standard care | p value |
|---|---|---|---|
| Serum creatinine (mg/dL)* | 1.14 (0.80,1.46) | 1.05 (0.84,2.08) | 0.49 |
| eGFR (mL/min/1.73 m2)* | 66.74 (30.77) | 61.23(35.16) | 0.54 |
| UACR (mg/g)* | 36.83 (13.39,131.90) | 177.70 (47.12,745.71) | 0.036 |
| MAKE 365, n (%)a | 13/40 (32.5%) | 11/38 (28.9%) | 0.73 |
| Death, n (%) | 7/40 (17.1%) | 5/38 (12.8%) | 0.59 |
| RRT, n (%) | 6/33 (18.2%) | 3/33 (9.1%) | 0.28 |
| Doubling serum creatinine, n (%) | 1/33 (3.0%) | 4/33 (12.1%) | 0.36 |
| Renal recovery, n (%)b | 8/16 (50%) | 4/11 (36.4%) | 0.70 |
| New RRT, n (%)c | 1/28 (3.6%) | 2/31 (6.5%) | 0.62 |
| New CKD, n (%)d | 3/22 (13.6%) | 4/19 (21.1%) | 0.69 |
| CKD progression, n (%)e | 7/11 (63.6%) | 11/14 (78.6%) | 0.41 |
| Progression of albuminuria, n(%)f | 2/33 (6.1%) | 6/33 (18.2%) | 0.26 |
| Recurrent AKI, n (%)g | 6/33 (18.2%) | 6/33 (18.2%) | 1.00 |
| Readmission, n (%)h | 27/49 (55.1%) | 24/49 (49%) | 0.54 |
| Blood pressure control, n (%)i | 29/33 (87.9%) | 19/33 (57.6%) | 0.006 |
| RAAS inhibitor use, n (%) | 18/33 (54.5%) | 14/33 (42.4%) | 0.33 |
| 24-h urine sodium (mmol) | 112.82 (63.17) | 127.69 (54.23) | 0.35 |
| 24-h dietary protein intake (g/kg/d) | 1.01 (0.32) | 0.85 (0.28) | 0.07 |
| Albumin (g/dL) | 4.1 (3.8,4.4) | 4.0 (3.8,4.4) | 0.59 |
| EQ-5D-5L index scoresj | 0.96 (0.90,1.00) | 0.99 (0.80,1.00) | 0.80 |
Significant values are shown in bold type, *Data excluded patients with RRT
AKI, acute kidney injury; CKD, chronic kidney disease; GFR, glomerular filtration rate; RAAS, renin–angiotensin–aldosterone-system; RRT, Renal replacement therapy; SD, standard deviation; UACR, urine albumin creatinine ratio
aMAKE 365; major adverse kidney events at 365 d were comprised of death, incident dialysis (requirement for CRRT), and persistent renal dysfunction death (doubling of serum creatinine or eGFR < 50% from baseline)
bRenal recovery; serum creatinine level had returned to baseline or < 1.5 times from baseline and not ongoing need for RRT or currently receiving RRT (only patients who were non-recovery at discharge)
cNew RRT; new case of RRT
dNew CKD; newly diagnosis of chronic kidney disease by eGFR criteria in no previous history of CKD
eCKD progression; change of staging of CKD by eGFR criteria in previous history of chronic kidney disease
fProgression of albuminuria; change in staging of albuminuria criteria from at 3 months to 12 months post-discharge
gRecurrent AKI; document of AKI definition by KDIGO 2012 criteria
hReadmission; episode of unplanned readmission
iBlood pressure control; blood pressure < 140/90 mmHg in non-hypertensive patients or < 130/80 mmHg in hypertensive patients
jEQ-5D-5L index scores; descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, self-care, usual activities, pain and discomfort and anxiety and depression)